FinancialInformation
Investor Resources
-
Q2 FY24 Results Sheet
-
Q1 FY24 Results Sheet
-
Q4 FY23 Results Sheet
-
Q3 FY23 Results Sheet
-
Q2 FY23 Results Sheet
-
Q1 FY23 Results Sheet
-
Q4 FY22 Results Sheet
-
Q3 FY22 Results Sheet
-
Q2 FY22 Results Sheet
-
Q1 FY22 Results Sheet
-
Q4 FY21 Results Sheet
-
Q3 FY21 Results Sheet
-
Q2 FY21 Results Sheet
-
Q1 FY21 Results Sheet
-
Q4 FY20 Results Sheet
-
Q3 FY20 Results Sheet
-
Q2 FY20 Results Sheet
-
Q1 FY20 Results Sheet
-
Q4 FY19 Results Sheet
-
Q3 FY19 Results Sheet
-
Q2 FY19 Results Sheet
-
Q1 FY19 Results Sheet
-
Q4 FY18 Results Sheet
-
Q3 FY18 Results Sheet
-
Q2 FY18 Results Sheet
-
Q1 FY18 Results Sheet
-
Q4 FY17 Results Sheet
-
Q3 FY17 Results Sheet
-
Q2 FY17 Results Sheet
-
Q1 FY17 Results Sheet
-
Q4 FY16 Results Sheet
-
Q3 FY16 Results Sheet
-
Q2 FY16 Results Sheet
-
Q1 FY16 Results Sheet
-
Q4 FY15 Results Sheet
-
Q3 FY15 Results Sheet
-
Q2 FY15 Results Sheet
-
Q1 FY15 Results Sheet
-
Q4 FY14 Results Sheet
-
Q3 FY14 Results Sheet
-
Q2 FY14 Results Sheet
-
Q1 FY14 Results Sheet
-
Q2 FY24 Investor Presentation
-
Q1 FY24 Investor Presentation
-
Q4 FY23 Investor Presentation
-
Q3 FY23 Investor Presentation
-
Presentation at JP Morgan Healthcare Conference, SFO US
-
Q2 FY23 Investor Presentation
-
Q1 FY23 Investor Presentation
-
Q4 FY22 Investor Presentation
-
Q3 FY22 Investor Presentation
-
Q2 FY22 Investor Presentation
-
Q1 FY22 Investor Presentation
-
General Investor Presentation August 2021
-
Q4 FY21 Investor Presentation
-
Q3 FY21 Investor Presentation
-
Q2 FY21 Investor Presentation
-
Analyst Day Presentation, March 2021
-
Q2 FY24 Press Release
-
Q1 FY24 Press Release
-
Q4 FY23 Press Release / News
-
Q3 FY23 Press Release / News
-
Press Release in relation to acquisition of ‘Razel’ franchise from Glenmark Pharmaceuticals Limited
-
Q2 FY23 Press Release / News
-
Q1 FY23 Press Release / News
-
Q4 FY22 Press Release
-
Q3 FY22 Press Release
-
Q2 FY22 Press Release
-
Q1 FY22 Press Release
-
Press Release in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited
-
Press Release regarding the launch of Molupiravir for the Indian market
-
Q4 FY21 Press Release
-
Q3 FY21 Press Release
-
Q2 FY21 Press Release
-
Q1 FY21 Press Release
-
Q2 FY20 Press Release
-
Q1 FY20 Press Release
-
Q4 FY19 Press Release
-
Q3 FY19 Press Release
-
Q2 FY19 Press Release
-
Q1 FY19 Press Release
-
Q4 FY18 Press Release
-
Q3 FY18 Press Release
-
Q2 FY18 Press Release
-
Q1 FY18 Press Release
-
Q4 FY17 Press Release
-
Q3 FY17 Press Release
-
Q2 FY17 Press Release
-
Q1 FY17 Press Release
-
Q4 FY16 Press Release
-
Q3 FY16 Press Release
-
Q2 FY16 Press Release
-
Q1 FY16 Press Release
-
Q4 FY15 Press Release
-
Q3 FY15 Press Release
-
Q2 FY15 Press Release
-
Q1 FY15 Press Release
-
Q4 FY14 Press Release
-
Q3 FY14 Press Release
-
Q2 FY14 Press Release
-
Q1 FY14 Press Release
-
Q3 FY13 Press Release
-
Q2 FY13 Press Release
-
Q1 FY13 Press Release
-
Q2 FY24 Earnings Call Audio
-
Q1 FY24 Earnings Call Audio
-
Q4 and FY23 Earnings Call Audio
-
Q3 FY23 Earnings Call Audio
-
Q2 FY23 Earnings Call Audio
-
Q1 FY23 Earnings Call Audio
-
Q4 and FY 22 Earnings Call Audio
-
Q3 FY 22 Earnings Call Audio
-
Audio recordings of Investors call- 27.01.2022
-
Q2 FY22 Earnings Call Audio
-
Q1 FY22 Earnings Call Audio
-
Q4 FY21 Earnings Call Audio
-
Q2 FY 24 Earnings Call Transcript
-
Q1 FY 24 Earnings Call Transcript
-
Q4 FY 23 Earnings Call Transcript
-
Q3 FY 23 Earnings Call Transcript
-
Q2 FY 23 Earnings Call Transcript
-
Q1 FY 23 Earnings Call Transcript
-
Q4 FY 22 Earnings Call Transcript
-
Q3 FY 22 Earnings Call Transcript
-
Transcript of Investors call on 27.1.2022 in relation to Acquisition of Brands and Related Assets from Sanzyme
-
Q2 FY22 Earnings Call Transcript
-
Q1 FY22 Earnings Call Transcript
-
Q4 FY21 Earnings Call Transcript
IR & Shareholders Contact
For Shareholders:
Company Secretary
Cnergy IT Park, Unit A2, 3rd floor,
Appa Saheb Marathe Marg,
Prabhadevi, Mumbai 400 025.
India.
Tel No. 91-22-2439 5200 / 2439 5500
Fax No. 91-22-2431 5331 / 2431 5334
Email: investorelations@jbpharma.com
For Transfer/Transmission of Shares :
Datamatics Business Solutions Ltd.
Plot No. B 5, Part B Crosslane,
MIDC, Andheri (East), Mumbai 400 093.
India
Contact Person: Mr. Satish Patil
Tel No. (022) 6671 2001-06
Fax No. (022) 6671 2011
Email: corpequity@dfssl.com
Nodal Officer for the Purpose of
Coordination with IEPF Authority:
Company Secretary
Cnergy IT Park, Unit A2, 3rd floor,
Appa Saheb Marathe Marg, Prabhadevi,
Mumbai 400 025.
India.
Tel No. 91-22-2439 5200 / 2439 5500
Fax No. 91-22-2431 5331 / 2431 5334
Email: investorelations@jbpharma.com
Note : This page is currently being updated.